Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises A3P Biomedical in conjunction with directed share issue
Mandate

Vinge advises A3P Biomedical in conjunction with directed share issue

May 05, 2022 M&A

Vinge has advised A3P Biomedical in connection with an issue of shares amounting to SEK 400 million directed at Stena Sessan AB, TomEqt Private AB, Flerie Invest AB, Östersjöstiftelsen and Inbox Capital. A3P Biomedical specialises in advanced diagnostics of prostate cancer.

Vinge’s team primarily consisted of Johan Winnerblad, Rikard Lindahl, William Kåge, Lorin Arabi, Gabriel Chabo, Stojan Arnerstål, Arvid Axelryd and Olivia Belding.

Related

Vinge advises Altor- and Stena-owned Gunnebo in connection with the divestment of Gunnebo Entrance Control AB to ASSA Abloy

 Vinge has advised Gunnebo in connection with its divestment of Gunnebo Entrance Control AB to ASSA Abloy.
August 04, 2026

Vinge advises Precise Biometrics in connection with rights issue
July 24, 2026

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

 Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026